Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal

Status Completed

Clinical Trial Summary

The purpose of he study is to evaluate effects of dexmedetomidine on pain during radiofrequency ablation of liver and kidney tumours.

Clinical Trial Description

Although radiofrequency ablation (RF) is accepted as the best therapeutic choice for patients with early stage hepatocellular carcinoma when liver transplantation or surgical resection are not suitable options, it is still performed only in a few hospitals and experience is so far limited (Goldberg & Ahmed, 2002; Shiina et al., 2005). In addition, RF ablation is emerging as a viable alternative to surgery for inoperable patients with limited hepatic metastatic disease, especially from colorectal cancer. Although radiofrequency ablation has been accepted as a safe and effective treatment for liver and kidney tumours, there are few studies addressing periprocedural pain.

Thus, the optimal anaesthetic procedure is still to be determined. Currently at our institution RF is performed as monitored sedation procedure using remifentanil infusion supplemented with midazolam boluses, when considered necessary. However, when using remifentanil and midazolam combination it is quite difficult to avoid too deep respiratory depression.

Dexmedetomidine is an α2-adrenoreceptor agonist with sedative, analgesic and anxiolytic effects, and it has more selective α2-adrenergic effect than clonidine. Dexmedetomidine has a great deal of potential in this arena given its analgesic and anxiolytic properties while preserving respiratory drive (Bergese SD et al., 2010).

All patients will receive dexmedetomidine 0.4 µg/kg/hr infusion from the start of procedure. The infusion will be continued during the whole RF procedure.

At the same time all patients will receive remifentanil infusion according to TCI (target controlled infusion) protocol. Plasma concentration target will be set from 0.5 ng/ml and, if necessary, will be increased to achieve a comfortable state of patient (Ramsey Sedation Scale: 2-3). ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02016391
Study type	Interventional
Source	Uppsala University Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	December 2013
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01627808` - Fluid Optimization in Liver Surgery	N/A
Withdrawn	`NCT05109052` - Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma	Phase 1/Phase 2
Recruiting	`NCT05179824` - Tempus Priority Study: A Pan-tumor Observational Study
Recruiting	`NCT03896958` - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Completed	`NCT05030090` - Integrative Nutrition Care Plan for the Patient With Liver and Colorectal Cancer	N/A
Terminated	`NCT00669136` - Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma	Phase 1
Not yet recruiting	`NCT05041335` - Wet Heparinized Suction for Abdominal Cancer	N/A
Recruiting	`NCT04258813` - Onco-primary Care Networking to Support TEAM-based Care	N/A
Completed	`NCT03299036` - Drug-loadable（T-ACE Beads）for Hepatoma Embolization Therapy	N/A
Recruiting	`NCT03323996` - Impact of a Training in Therapeutic Education on the Relation Between Care Givers and Their Patients	N/A
Not yet recruiting	`NCT06458998` - Getting To Implementation: Improving Cancer Screening for Veterans	N/A
Completed	`NCT02044224` - Effects of Dexmedetomidine During IRE Procedures for Solid Tumours	Phase 4
Not yet recruiting	`NCT03607643` - A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies	Phase 1/Phase 2
Completed	`NCT05643833` - Impact of Gender on the Outcome of Liver Transplantation for Hepatocellular Carcinoma
Recruiting	`NCT03452774` - SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Not yet recruiting	`NCT03766776` - Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)	N/A
Recruiting	`NCT00730860` - Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE	N/A
Terminated	`NCT00216437` - Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma	Phase 1
Completed	`NCT04172714` - Low-dose Y90 Treatment Planning for HCC	N/A
Active, not recruiting	`NCT03347162` - Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms